Experience of using the combined drug Mioreol in patients with Alzheimer’s disease and mixed dementia

Zaharov V.V.; Koberskaya N.N.

doi:https://doi.org/10.17116/jnevro202412409134

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-8447-3264

Koberskaya N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-3110-4764

Experience of using the combined drug Mioreol in patients with Alzheimer’s disease and mixed dementia

Authors:

Zaharov V.V., Koberskaya N.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9): 34‑43

DOI: 10.17116/jnevro202412409134

Read: 1687 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zaharov VV, Koberskaya NN. Experience of using the combined drug Mioreol in patients with Alzheimer’s disease and mixed dementia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):34‑43. (In Russ.)
https://doi.org/10.17116/jnevro202412409134

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

The aim of the study was to evaluate the clinical efficacy, safety, and tolerability of a fixed-dose combination of donepezil and memantine (Mioreol) in patients with Alzheimer’s disease (AD) and AD with cerebrovascular pathology.

MATERIAL AND METHODS

497 patients with moderate to severe dementia, average age 75.4+6.81 years, received Mioreol (donepezil 10 mg+memantine 20 mg). Treatment efficacy was assessed using the MMSE, clock drawing, Sandoz Clinical Geriatric Scale, and Clinical Global Impressions after 3 months of therapy. All adverse events during treatment were recorded.

RESULTS

The transition to Mioreol was accompanied by a reliable improvement in cognitive functions, emotional-behavioral indicators and neuropsychiatric status in general.

CONCLUSIONS

Mioreol demonstrated clinical efficacy, safety and good tolerability in patients with AD and AD with cerebrovascular pathology with moderate to severe dementia syndrome.

Keywords:

Alzheimer’s disease

Alzheimer’s disease with cerebrovascular pathology

dementia

basic therapy for dementia

donepezil

memantine

Mioreol

Authors:

Zaharov V.V.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-8447-3264

Koberskaya N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-3110-4764

Received:

27.08.2024

Accepted:

30.08.2024

Close metadata

References:

Prince M. World Alzheimer Report 2015. The Global Impact of Dementia — An Analysis of Prevalence, Incidence, Cost and Trends. 2015. https://www.alzint.org/u/WorldAlzheimerReport2015.pdf
Prince M, Prina M, Guerchet M. The world Alzheimer’s report 2013. Journey of caring: an analysis of long-term care for dementia. https://www.alz.co.uk/research/worldalzheimerreport2013.pdf
Saxena S. Dementia world report: a public health priority. Geneva, Switzerland: World Health Organization. 2012.
Wimo A, Prince M. The world Alzheimer’s report 2010: the global impact of dementia. Alzheimer’s disease International. Published 21 September 2010. https://www.alz.org.documents/national/world_alzeimer_report_2010.pdf
Briggs R, Kennelly SP, O’Neill D. Drug Treatments in Alzheimer’s Disease. Clin Med. 2016;16:247-253. https://doi.org/10.7861/clinmedicine.16-3-247
Atri A. Current and Future Treatments in Alzheimer’s Disease. Semin Neurol. 2019;39:227-240.
Singh B, Day CM, Abdella S, Garg S. Alzheimer’s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024;367:402-424. https://doi.org/10.1016/j.jconrel.2024.01.047
Clinical guidelines. Cognitive disorders in elderly and senile persons. Ministry of Health of the Russian Federation. 2020. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev. 2004;1:CD004395.
Orgogozo JM, Rigaud AS, Stoffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839.
Roman GC, Salloway S, Black SE, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 2010;41:1213-1221.
Wilcock G, Mobius HJ, Stoffler A. MMM 500 Group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-300.
Cummings JL, Tong G, Ballard C. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis. 2019;67(3):779-794. https://doi.org/10.3233/JAD-180766
Riverol M, Slachevsky A, López OL. Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer’s Disease: A Literature Review Evidence. Eur Neurol J. 2011;3(1):15-19.
Tariot PN, Farlow MR, Grossberg GT, et al. Memantine and Donepezil for Alzheimer’s Disease. JAMA. 2004;291(3):317-324. https://doi.org/10.1001/jama.291.3.317
Kamalakkannan BS, Parkar G. Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-719.
Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002;16:203-212.
Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med. 2004;128(1):32-38.
Hulette CM. Brain banking in the United States. J Neuropathol Exp Neurol. 2003;62(7):715-722.
Knopman DS, Parisi JE, Boeve BF, et al. Vascular dementia in a population-based autopsy study. Arch Neurol. 2003;60:569-575.
Nolan KA, Lino MM, Seligmann AW, Blass JP. Absence of vascular dementia in an autopsy series from a dementia clinic. J Am Geriatr Soc. 1998;46(5):597-604.
Yakhno NN, Preobrazhenskaya IS, Zakharov VV, et al. Prevalence of cognitive impairment in neurological diseases (analysis of the work of a specialized outpatient clinic). Neurology, Neuropsychiatry, Psychosomatics. 2012;2:30-33. (In Russ.).